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Abstract
We explore the prediction of individuals’ phenotypes for complex traits using genomic data. We compare several widely used
prediction models, including Ridge Regression, LASSO and Elastic Nets estimated from cohort data, and polygenic risk scores
constructed using published summary statistics from genome-wide association meta-analyses (GWAMA). We evaluate the
interplay between relatedness, trait architecture and optimal marker density, by predicting height, body mass index (BMI) and
high-density lipoprotein level (HDL) in two data cohorts, originating from Croatia and Scotland. We empirically demonstrate
that densemodels are betterwhen all genetic effects are small (height and BMI) and target individuals are related to the training
samples, while sparsemodels predict better in unrelated individuals andwhen some effects havemoderate size (HDL). For HDL
sparse models achieved good across-cohort prediction, performing similarly to the GWAMA risk score and to models trained
within the same cohort, which indicates that, for predicting traits withmoderately sized effects, large sample sizes and familial
structure become less important, though still potentially useful. Finally, we propose a novel ensemble of whole-genome
predictors with GWAMA risk scores and demonstrate that the resulting meta-model achieves higher prediction accuracy than
either model on its own. We conclude that although current genomic predictors are not accurate enough for diagnostic
purposes, performance can be improved without requiring access to large-scale individual-level data. Our methodologically
simple meta-model is a means of performing predictive meta-analysis for optimizing genomic predictions and can be easily
extended to incorporate multiple population-level summary statistics or other domain knowledge.
† The authors wish it to be known that, in their opinion, the last two authors should be regarded as joint Last Authors.
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Introduction
Since the completion of the sequence of the human genome, ac-
curate prediction of complex phenotypic traits from genotypes
has become a central goal of biomedical research. Since genetic
information remains largely unchanged through life, it is often
argued that byapplying our knowledge about the human genome
to medical practice at the level of the individual patient, we can
improve disease management in terms of prevention, diagnosis
and treatment, thus optimizing the health care each individual
receives (1,2) from as early as birth. For example, we can apply
genetic testing to identify andmonitor individualswith high gen-
etic risk of disease, we can discriminate different subtypes of
complex diseases, and we can do better targeting of treatments
through pharmacogenomics. Promising ﬁndings from Genome-
Wide Association Studies (GWAS) that are currently being trans-
lated into clinical use are discussed in a recent review byManolio
(3). These include increased prediction accuracy of Type 1 dia-
betes mellitus when comparing a model using all GWAS-identi-
ﬁed genomic markers to a model using only markers in the
Major Histocompatibility Complex (4), identiﬁcation of C-reactive
protein as a potential biomarker for the HNF1A-MODYmonogen-
ic form of diabetes (5), and better understanding and manage-
ment of simvastatin-induced myopathy risk (6).
However, for most complex traits the adoption of gene-based
personalized approaches to medical care remains limited. One
reason is that clinical adoption of scientiﬁc discoveries can be
slow in general. In the case of GWAS ﬁndings, clinical translation
can be further prolonged by (i) the fact that the underlying bio-
logical mechanisms are often not well understood and (ii) the
wide range of different expertise needed to initiate and imple-
ment genomic interventions (7,8). A second reason for the lim-
ited application of GWAS ﬁndings to medical care is the low
predictive accuracy achieved by current genomic predictors of
most complex human traits, including highly heritable traits
such as height (9–11).
In human genetics, the task of genomic prediction has been
most commonly addressed by considering results from GWAS.
To make predictions, single-nucleotide polymorphisms (SNPs)
that meet a predeﬁned statistical signiﬁcance threshold of asso-
ciation with the trait are considered and a genetic score is con-
structed by adding the estimated effects of the alleles each
individual carries for these SNPs (12). In order to reduce the num-
ber of false-positive associations, a stringent signiﬁcance thresh-
old is typically applied, which means that only a dozen to a few
hundred SNPs are considered in the genetic score. Furthermore,
since the effect of each SNP is estimated separately, care must
be taken to exclude SNPs that ‘tag’ the same causal locus (13).
This can be performed by only considering the SNP with the low-
est P-value within each region, or by pruning SNPs according to a
predeﬁned threshold on linkage disequilibrium (LD). Such heur-
istic approaches can be computationally expensive, and more
importantly, are likely to include markers that are redundant,
or exclude markers that carry complementary information to
the already included ones, or both. GWAS-based genetic (or poly-
genic) risk scores have been used for prediction in a number of
common diseases (12–15), and although some predictive ability
is demonstrated, the accuracies achieved to date fall short of clin-
ical utility.
A different approach to GWAS-based polygenic score con-
structions is to use statistical methods that estimate the effects
for all SNPs jointly. Such approaches have been termed whole-
genome prediction methods (16), and were ﬁrst used as models
for SNP data in genomic selection in animal breeding (17).
An advantage of whole-genome prediction methods is that by
construction they take into account LD between SNPs. Perhaps
more importantly, the potential value of whole-genome predic-
tors lies in their ability to learn what is important for the predic-
tion task directly from the data, without the need to pre-select
the input SNPs based on (typically univariate) measures of asso-
ciationwith the trait. This property has become very important in
light of the inﬂuential paper of Yang et al. (18), who demonstrated
that by considering all the SNPs simultaneously, they could
explain a much greater proportion of the trait heritability, than
by considering only the few SNPs that pass the stringent associ-
ation test.
There is a broad range of methods that can be used to imple-
ment whole-genome prediction (19). These often differ in terms
of their prior assumptions regarding the distribution of SNP ef-
fects, which induce different estimation of model parameters.
Here we are interested in comparing methods with respect to
the number of genetic markers that are included in the resulting
predictor, which we refer to as the sparsity level, with sparsemod-
els considering tens to a few hundredmarkers and densemodels
considering hundreds of thousands of markers. In the context of
genomic prediction of complex traits, it is not yet clear when
dense or sparsemodels are optimal. For genomic selection in ani-
mal breeding, de los Campos et al. (19) consider more than 50
studies that compare different estimationmethods and conclude
that, in empirical analyses of real data, there are only small dif-
ferences between methods, with estimation methods leading to
sparse models having a slight advantage. However, this relative
performance is mainly based on livestock populations, which
typically exhibit high LD and are genotyped using relatively
sparse platforms (in the order of 50 000 SNPs), and hence may
change when we examine genomic prediction of complex traits
in humans, where LD is not as high and the genotyping platforms
are denser. In plant breeding, Wimmer et al. (20) recommend that
dense whole-genome models should be preferred over sparse
ones, since most traits of agronomic performance are assumed
to have many small genetic effects, and medium trait heritabil-
ities, while the genomic data exhibit a large extent of LD.
In human genetics, two recent studies (21,22) have compared
densewith sparsemodels using differentwhole-genome estima-
tion methods and polygenic score constructions. Abraham et al.
(21) ﬁnd that model performance depends on the genetic archi-
tecture of the trait, with sparse whole-genome estimation meth-
ods being better than dense estimation methods and polygenic
scores when modelling traits with large genetic effects concen-
trated in a few genomic regions, while all methods perform simi-
larly when predicting traits with no known large genetic effects.
Warren et al. (22) compare dense and sparse shrinkage methods
with polygenic scores in predicting two lipid traits with similar
genetic architectures. They ﬁnd that sparse estimation methods
achieve lower mean squared error than dense ones, when all the
SNPs are given as input to the model, but different estimation
methods have similar results when they select the optimal num-
ber of markers using a validation set.
In this work, we compare dense and sparse genomic predic-
tionmodelswith respect to trait genetic architecture and popula-
tion structure. Speciﬁcally, we consider different scenarios
regarding relatedness between training samples and the target
population and evaluate which models have good generalization
performance within a single cohort (related individuals) and
across different cohorts (unrelated individuals), and what are
the characteristics of the trait thatmake such generalization pos-
sible. In human genetics, the accuracy of genomic prediction is
often assessed using nominally unrelated individuals. However,
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familial structure is an important source of predictive signal,
with relatedness between training and target samples being
one of the most important factors affecting predictive perform-
ance both in animal breeding (19) and in human complex traits
(23–25). As more individuals are genotyped and summary statis-
tics from different cohorts are aggregated to increase statistical
power, familial relationships for an increasing number of indivi-
duals will be available and hence there is a need to learn how to
best utilize this signal. To our knowledge, this is the ﬁrst study
that examines the interplay between relatedness, trait genetic
architecture and optimal model sparsity in the prediction of
complex traits in humans.
Furthermore, we evaluate the predictive value of genome-
wide associationmeta-analyses (GWAMA) by comparing the per-
formance of models estimated from our data cohorts to that of a
polygenic risk score constructed using only GWAMA ‘hits’ and
their GWAMA estimated effects, which are based on more than
100 000 individuals. Our ﬁnal contribution is the construction
and evaluation of a simple meta-model that combines dense
whole-genome predictors with GWAMA-based polygenic risk
scores. Current limitations in genomic prediction of complex
traits include incomplete genomic information (26,27), which
means that some causal loci are poorly tagged by the genotyped
SNPs, and lack of statistical power to detect true associations
(26,28,29), which means that the predictive signal is difﬁcult to
separate from the data noise. Our meta-model partly addresses
the ﬁrst limitation by exploiting the familial structure captured
by dense whole-genome predictors, and increases the statistical
power through the GWAMA risk score, which is based on sum-
mary statistics from the largest sample size currently available.
Results
In the following sections, we evaluate and compare a number of
different genomic predictors in within and across-cohort predic-
tion and explore how we can increase prediction accuracy by
combining models, or optimizing our experimental design. We
consider a GWAMA-based polygenic score and three penalized
regression methods, Ridge Regression (RR) (30), the Least Abso-
lute Shrinkage and Selection Operator (LASSO) (31) and the Elas-
tic Net (EN) (32). RR results in densemodels, while LASSO and EN
can result in sparse models by assigning a zero coefﬁcient to
some markers. The penalized regression methods are applied
using all available genotyped markers (267 912 SNPs) or subsets
of the genotyped markers selected based on GWAS pre-ﬁltering
(using our population data). The GWAMA-based scores are sparse
by construction—we only include the SNP ‘hits’ from the pub-
lished GWAMA study for each trait (33–35). These SNP ‘hits’ are
signiﬁcantly associatedwith the trait at the genome-wide signiﬁ-
cance threshold and LD is taken into account, typically by report-
ing only the most signiﬁcant association within each genomic
region. For SNP ‘hits’ that are not directly genotyped in our
data, we use imputed dosages when constructing the GWAMA-
score. To quantify prediction accuracy, we use the Pearson’s
correlation coefﬁcient between the true and the predicted pheno-
types. We use three types of data sets in our experiments. The
training data are used for parameter estimation, the validation
data are used for model selection (e.g. to select the optimal pen-
alty strength in the penalized regressionmethods) and the testing
data are used to estimate prediction accuracy. Throughout this
article, we always report prediction accuracy on the testing data.
More details are given in Materials and Methods.
We examine two data sets, namely Croatia and Orkney. These
differ in terms of familial and ancestry population structure. The
Croatian data set comprises individuals from three studies per-
formed at three locations—twoDalmatian islands and onemain-
land coastal city. TheOrkneydata set comprises individuals from
a single study, recruited with an emphasis on co-recruiting fam-
ilymembers. More details about the data cohorts are given inMa-
terials and Methods. The genomic relatedness in Croatia and
Orkney, estimated from the available 267 912 genotyped SNPs,
is presented in Figure 1. The proportion of familial to non-familial
relationships is higher in the Orkney cohort than it is in the
Croatian cohort.
Figure 1. Whole-genome Identity-By-State coefﬁcient of relationship between individuals in Croatia (left) and in Orkney (right). Each panel shows a histogram of the
genetic similarity between every pair of individuals from each data set. The sub-panels display in more detail the right tail of the histogram by zooming-in on the
y-axis. The similarity between individuals i and k is computed by sik ¼
1
P
XP
j¼1
ðxij  2 pjÞðxkj  2 pjÞ
2 pjð1 pjÞ
; where pj is the minor allele frequency (MAF) of SNP j, xij ∈ f0;1;2g is
the genotype of individual i at SNP j, and P = 267 912 (260 562 inOrkney) is the numberof the genotyped SNPs. Both cohorts contain related individuals, demonstrated in the
sub-panels by the density mass around 0.5 (expected IBS between parent-offspring and full siblings), 0.25 (expected IBS between half siblings and uncle/
aunt with nephew/niece) and 0.125 (expected IBS between ﬁrst cousins). The proportion of related individuals is higher in Orkney compared with Croatia,
demonstrated by the higher density in IBS values corresponding to familial relationships.
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We examine three complex traits, namely height, body mass
index (BMI) and high-density lipoprotein (HDL) cholesterol. The
genetic contribution to complex phenotypic traits is typically
analysed in terms of trait heritability, i.e. the amount of phenotyp-
ic variance that can be attributed to genetic effects, and in terms
of genetic architecture, which describes the number, effect sizes,
allele frequencies and modes of action of the genetic variants
affecting a trait, and is difﬁcult to infer in complex traits and
thus largely unknown. Current heritability benchmarks suggest
high, lowandmoderate contributions of genetic effects in height,
BMI and HDL, respectively (36). Additionally, empirical evidence
emerging from GWAS and GWAMA studies—which test trait
association with common SNPs—suggests that these three traits
differ in terms of the distribution of effect sizes for the ‘interro-
gated’ genetic variants. More speciﬁcally, although the evidence
is suggestive of a polygenic architecture for all three traits, in
height and BMI all the GWAMA-estimated SNP effects have
small magnitude, whereas in HDL there is a small number of
SNPs with moderate effect sizes in addition to a large number
of SNPs with small estimated effect sizes (33–35).
Heritability estimates for the three traits are given in Table 1.
The ﬁrst two columns show heritability estimates using all the
samples in each of our two cohorts (both related and unrelated
individuals) and are computed using a linear random-effects
model and all available genotyped SNPs. The last two columns
show heritability estimates reported in the literature. Both re-
ported estimates use common SNPs across the whole genome;
the ﬁrst one is computed using only related individuals, and
thus can be interpreted as a proxy for heritability estimated in
family studies, while the second one is computed using only
unrelated individuals. Due to the existence of familial relation-
ships in our data cohorts, our genomic heritability estimates
are close to the reported ‘family-based’ heritability of each trait,
which is higher than the heritability captured by common SNPs
in cohorts of unrelated individuals.
Histograms of GWAMA-estimated SNP effects for each of the
three traits are presented in Supplementary Material, Figure S1.
The fat right tail of the histogram for HDL illustrates the existence
of some SNPs with moderate effect sizes.
Within-cohort prediction
Figure 2A and B show accuracy (correlation coefﬁcient and 95%
conﬁdence interval) in within-cohort prediction from three pe-
nalized regression models—LASSO, EN and RR—as we increase
the number of SNPs that are given as input to the model. The
input SNPs are selected using the GWAS-based pre-ﬁltering
procedure (seeMaterials andMethods). The plots in (A) showpre-
diction accuracy when the training, validation and testing steps
are performed using samples from the Croatian populations
(nested cross-validation design), while the plots in (B) show pre-
diction accuracy when the training, validation and testing steps
are performed using individuals from Orkney (nested cross-
validation design). Rows correspond to different traits.
First, we want to assess if prediction of complex traits is pos-
sible using data cohorts with a few thousand individuals. The pe-
nalized regression model (type of model and number of input
SNPs) that achieves the highest accuracy in the validation step
is depicted by a black ‘x’ symbol in Figure 2. This optimal model
from the validation step also achieves the highest accuracy on
the testing data for all traits and both populations. Furthermore,
performance of RR trained using all 267 912 available SNPs is
always close or equal to that of the best within-cohort predictor.
Therefore, performance in this set of experiments can be maxi-
mized by either selecting the optimal penalty type and number
of inputmarkers through avalidation step, or by choosing a priori
a dense, whole-genome predictor. The absolute value of the cor-
relation coefﬁcient between true and predicted phenotypes for
the optimal penalized regression model is related to the herit-
ability of the trait, which is consistent with the literature
(25,26). In both populations, the accuracy achieved for height is
higher than the accuracy achieved for HDL, which is in turn high-
er than the accuracy for BMI, and height has the highest esti-
mated heritability followed by HDL and then BMI. Furthermore,
the level of accuracy achievable by penalized regressionmethods
depends on the population structure, and more speciﬁcally on
the extent of familial structure in the data. As illustrated in
Figure 1, the proportion of familial relationships is higher in the
Orkney data set than it is in Croatia, and in Figure 2, the accuracy
of the optimal penalized regression model is higher in Orkney
than it is in Croatia for all three traits. Additionally, the related-
ness between training and testing samples resulting from the
nested cross-validation split is as follows: in Orkney 88% of the
testing samples have at least one nominal relative in the training
data—genome-wide Identity-By-State (IBS) similarity ≥0.1—as
opposed to 52% in Croatia.
Comparing the different penalized regression models, we can
see that in within-cohort prediction, dense models (RR or many
input and retained SNPs) tend to outperform sparse models
(LASSO and EN or few input SNPs). In all cases, the performance
of penalized regression models using the top 5, 10 and in most
cases 100 SNPs (ranked by GWAS P-value in the training data) is
lower than that of denser models using thousands of SNPs. This
difference is statistically signiﬁcant in height and BMI, based on
Table 1. Heritability estimates in our cohort data and reported in the
literature
Trait bh2SNP;Croatia bh2SNP;Orkney bh2related;pub bh2unrelated;pub
Height 0.81 0.90 0.88 (0.09) (36) 0.46 (0.05) (36)
BMI 0.29 0.56 0.34 (0.12) (36) 0.14 (0.05) (36)
HDL 0.57 0.61 0.48 (0.11) (36) 0.12 (0.05) (36)
bh2SNP;Croatia: Estimated using all 267 912 genotyped SNPs and a linear
random-effects model (polygenic function in the GenABEL R
package). Each trait is adjusted for the effects of sex, age and age2
and the residuals are then z-transformed. HDL is additionally log-
transformed as aﬁrst step (i.e. before adjusting for the effects of sex,
age and age2). This pre-processing is performed separately for each
of the three Croatian sub-cohorts (Korcula, Vis and Split) and the
transformed phenotypes are then considered jointly in the linear
random-effects model.
bh2SNP;Orkney: Estimated using all 260 562 genotyped SNPs and a linear
random-effects model (polygenic function in the GenABEL R
package). Each trait is adjusted for the effects of sex, age and age2
and the residuals are then z-transformed. HDL is additionally log-
transformed as aﬁrst step (i.e. before adjusting for the effects of sex,
age and age2).
bh2related;pub: Estimated using common SNPs and 530 related individuals
from the ARIC study. Individuals were selected to have at least one
relative in the data, and relatives were deﬁned as having genome-
wide SNP similarity between 0.35 and 0.65, derived empirically [see
(36) for details].bh2unrelated;pub: Estimated using common SNPs and 5647 unrelated
individuals from the ARIC study, with genome-wide SNP
relationships below 0.025 [see (36) for details].
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a Fisher z-transformation of the correlation coefﬁcient (see Mate-
rials and Methods). On the other hand, the performance of sparse
penalized regression models is comparable and occasionally bet-
ter to that of dense models in HDL. Additionally, in all traits and
both populations there is a plateau in performance with respect
to the number of input SNPs; after we have included the top
10 000 to 25 000 SNPs, further increasing the number of input
SNPs does not lead to an increase in prediction accuracy. Interest-
ingly, the optimal penalized regressionmodel—selected based on
performance on the validation data—is always RR with at least
1000 SNPs and in 5 out of 6 cases more than 25 000 SNPs, which
correspond to dense whole-genome predictors after we have per-
formed the initial GWAS-based ﬁltering of markers.
Next, we compare the accuracy of within-cohort prediction to
the accuracy achieved by the GWAMA-based polygenic score. The
optimal penalized regressionmodel performs equallywell or bet-
ter than the GWAMA-based polygenic score in many cases, and
we empirically observe that this difference in performance de-
pends on the trait architecture and the level of relatedness in
the study cohort. The optimal penalized regressionmodel signiﬁ-
cantly outperforms the GWAMA-based polygenic score when
predicting height and BMI in Orkney, and achieves similar accur-
acy to the polygenic score when predicting height and BMI in
Croatia, suggesting that in traits with many small effects, the fa-
milial structure may be better at representing the predictive sig-
nal in the data, compared with the GWAMA hits. On the other
hand, the GWAMA score signiﬁcantly outperforms the optimal
penalized regression model when predicting HDL in Croatia,
and the two methods have similar accuracy in Orkney. This sug-
gests that when the trait has at least some SNPs with moderate
genetic effects, then the GWAMA score could be advantageous
over prediction models estimated from single-cohort data, as
common SNPs with large or moderately sized genetic effects
are easier to identify and estimate accurately in a GWAMA.
An interesting question regarding prediction accuracy, espe-
cially in the case of height and BMI, is what happens if we use a
genetic predictor based solely on pedigree information from our
two cohorts. We construct a SNP-based proxy for pedigree by
applying a threshold to the genome-wide IBS similarity matrix
and setting relationships smaller than the threshold to zero,
thus only retaining relationships above a certain coefﬁcient of
relatedness. Results using this SNP-based pedigree are shown
in Supplementary Material, Table S1. The SNP-based pedigree
leads to decreased performance compared with the optimal
penalized regression model, and performance becomes worse
as we apply higher thresholds on the IBS similarity matrix,
i.e. as we restrict the SNP-based pedigree to higher degrees of
familial relationships.
To further empirically explore the effect of familial relation-
ships between training and testing samples on the performance
of penalized estimationmethods, we split the testing data in two
groups, individuals with at least one nominal relative (IBS≥ 0.1)
in the training data (referred to as ‘related’) and individuals
with no relatives in the training data (referred to as ‘unrelated’)
and compute prediction accuracy in each group. The results
from this analysis for LASSO and RR are presented in Figure 3,
together with the predictive correlation of the GWAMA score to
facilitate comparison. Performance in the ‘related’ group is
always better than that in the ‘unrelated’ group for LASSO and
RR and this difference increases as we consider denser models,
i.e. RR compared with LASSO, and many input SNPs compared
with fewer input SNPs. On the other hand, the performance of
the GWAMA score is very similar in the ‘related’ and the ‘unre-
lated’ groups.
Figure 3 suggests that the predictive signal in the dense
regression models is different to the predictive signal in the
GWAMA-based polygenic score method, with the former captur-
ing mostly familial structure and the latter capturing genetic
Figure 2. Accuracy of penalized regression models as we increase the number of input SNPs together with accuracy of the GWAMA-based polygenic score. (A) Within-
cohort prediction in Croatia. (B) Within-cohort prediction in Orkney. (C) Across-cohort prediction (training & validation: Croatia, testing: Orkney). y-axis: accuracy is
measured using the Pearson’s correlation coefﬁcient between the predicted and true phenotype of the testing samples. The error bar corresponds to the 95%
Conﬁdence Interval (upper CI). x-axis: an increasing number of SNPs (genetic markers) are given as input to the regression models. The SNP selection is performed by
GWAS pre-ﬁltering using the training data in each case. The number of input SNPs for the GWAMA-based risk score is constant (height: 180 SNPs, BMI: 32 SNPs, HDL:
70 SNPs). Black ‘x’ symbol: depicts the optimal penalized regression model—in terms of the type of shrinkage penalty and the number of input markers—based on
prediction accuracy on the validation set. This corresponds to the model that we would select as our best predictor in a real-world application.
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effects that generalize across many European populations by
construction. Our next analysis aims to assess whether we can
achieve better prediction accuracy by combining these two
sources of predictive signal. To this end, we construct a meta-
model by taking a linear combination of the two predictors,
namely the predicted value from the optimal penalized regres-
sionmodel and the GWAMA-based polygenic score (seeMaterials
and Methods).
The prediction accuracy of themeta-model is shown in Figure 4,
together with the prediction accuracy of the GWAMA score and of
the optimal penalized regression model. The prediction accuracy
achieved by the meta-model is always higher than that achieved
by either the polygenic score or penalized regression. Furthermore,
the performance achieved by the meta-model is often statistically
signiﬁcantly better compared with the performance of its compo-
nents, where statistical signiﬁcance is tested using a Fisher z-trans-
formation of the correlation coefﬁcient.
Finally, we wanted to assess if performance in within-cohort
prediction improves if we increase the sample size of our training
data by including individuals from a different population cohort.
Results from within-Orkney prediction where we include indivi-
duals from Croatia in training are shown in Supplementary
Material, Figure S2C. There are no statistically signiﬁcant changes
between this experimentand theOrkneywithin-cohort experiment
presented in Figure 2B. However, we cannote that for all three traits
the highest prediction accuracy is achieved when we use the com-
bined training data set, which suggests that it could be beneﬁcial to
train our predictivemodels using all available cohorts, even if some
of them are less closely related to the target population.
Across-cohort prediction
In this section, we examine which models can achieve good
generalization performance in across-cohort prediction, i.e.
when the target individuals come fromadifferent cohort (popu-
lation) to the training samples. Figure 2C shows the prediction
accuracy (correlation coefﬁcient and 95% conﬁdence interval)
of three penalized regression models—LASSO, EN and RR—
when the training and testing data come from south-east and
north-west Europe, respectively. Again, we evaluate perform-
ance in models with an increasing number of input SNPs,
selected by performing GWAS pre-ﬁltering on the training
data. In all the subﬁgures, the models are trained using all the
individuals from Croatia and prediction accuracy is measured
by considering the predicted and true phenotypes in all indivi-
duals from Orkney. The strength of the shrinkage penalty,
i.e. the meta-parameter that controls how much shrinkage is
applied on the model parameters, is selected based on samples
fromCroatia. Speciﬁcally, we use the penalty strength thatmax-
imizes the predictive correlation in within-cohort prediction in
Croatia. An alternative way of selecting the penalty strength is
presented in Supplementary Material, Figure S2B, where we
split the Orkney samples in 10-folds and iteratively use 9-folds
to select the optimal penalty strength (validation) and make
predictions on the held-out fold (testing). See Materials and
Methods for more details.
The penalized regression models trained using individuals
from Croatia are poor predictors for height and BMI in Orkney.
Figure 3. Accuracy of LASSO and RR in within-cohort prediction computed using ‘related’, ‘unrelated’ and ‘all’ testing individuals (IBS threshold = 0.1) together with
accuracy of the GWAMA-based polygenic score for the same individuals. The ‘related’ group (triangles) contains testing individuals with at least one nominal relative
in the training data (IBS≥ 0.1). The ‘unrelated’ group (squares) contains testing samples that are nominally unrelated to all the training samples. The ‘all’ group (circles)
contains all the testing samples. y-axis: accuracy is measured using the Pearson’s correlation coefﬁcient between the predicted and true phenotype of the
corresponding testing samples. x-axis: an increasing number of SNPs are given as input to the regression models (plotted in log-scale). The SNP selection is performed
by GWAS pre-ﬁltering using the training data in each case. Left: training, validation and testing are performed using samples from the Croatia dataset (nested cross-
validation design). Right: training, validation and testing are performed using samples from the Orkney dataset (nested cross-validation design). Performance in the
‘related’ group is always better than that in the ‘unrelated’ group for LASSO and RR and this difference increases as we consider denser models. Performance of the
GWAMA score is very similar in the ‘related’ and the ‘unrelated’ groups. The accuracies computed in ‘related’ and ‘unrelated’ groups based on a smaller IBS threshold
(IBS threshold = 1/16) are given in Supplementary Material, Figure S8.
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Irrespective of whether we use a dense or a sparse model,
prediction accuracy for height and BMI is low in across-cohort
prediction. Indeed, we cannot reject the null hypothesis of no
correlation between the true and the predicted phenotypes for
any of the penalized regression models with 99% conﬁdence.
For somemodels, we can reject the null hypothesiswith 95% con-
ﬁdence, but overall, the penalized regression models for height
and BMI trained using individuals from Croatia do not have
good generalization performance in the Orkney data set. In con-
trast, in across-cohort prediction of HDL (Fig. 2C, bottom row) the
accuracy of sparse models is statistically different to zero, and
signiﬁcantly higher than that of denser models (RR with many
input SNPs or LASSO and ENswithmany SNPs retained in the so-
lution). Additionally, the across-cohort prediction accuracy of
sparse models is not statistically different to that achieved by
the GWAMA-based polygenic score method in HDL, despite the
fact that the former is trained using a 100 times fewer samples
than the latter.
Furthermore, for across-cohort prediction of HDL, the per-
formance of RR becomes substantially worse as we increase
the number of input SNPs, while the performance of LASSO
and EN has a smaller decline to RR as we increase the number
of input SNPs from 5 to 500, and has no further decline as we
add more input SNPs. Interestingly, when the validation sam-
ples (used to select the optimal penalty strength) come from
Orkney (Supplementary Material, Fig. S2B), prediction accuracy
of the sparse estimation methods—namely LASSO and EN—
remains the same irrespective of the number of input SNPs.
The LASSO and EN models that achieve the optimal predictive
correlation are very sparse, with the number of retained SNPs
being 3 and 4 for the LASSO and EN, respectively. The retained
SNPs in LASSO are rs3764261—most signiﬁcant hit in the HDL
GWAMA, and also used in the polygenic score (GWAMA P-value
= 1 × 10−769), rs7499892—signiﬁcant in the HDL GWAMA, but not
reported in the paper as it is in the same region as rs3764261
(GWAMA P-value = 1 × 10−541), and rs1532085—4th most signiﬁ-
cant hit in the HDL GWAMA, and also used in the polygenic
score (GWAMA P-value = 1 × 10−188).
Discussion
Dense whole-genome predictors and relatedness
Our main goal is to compare different dense and sparse genomic
prediction models with respect to the genetic architecture of the
trait and the population structure of the study sample, primarily
in terms of relatedness. In ourﬁrst set of experiments,we showed
that in within-cohort prediction it is possible to exploit familial
structure and get good prediction accuracy using dense whole-
genome predictors. The dense whole-genome predictors act as
proxies of pedigree information and can often achieve higher
prediction accuracy than the GWAMA-based polygenic score,
despite using two orders of magnitude fewer samples (<3000
samples versus >100 000 samples, respectively) and lower cover-
age of the genome (<268 000 genotyped SNPs versus >2 000 000
SNPs tested for association in GWAMAs, respectively). It is inter-
esting to note that <30% of the GWAMA reported signiﬁcant SNPs
are genotyped in our data sets (22 out of 180 in height, 7 out of 32
in BMI and 20 out of 70 in HDL). This means that only a subset of
the GWAMA ‘hits’ is directly given as input to the penalized
regression models, since we only use genotyped SNPs as inputs
in this case. On the other hand, the majority of GWAMA ‘hits’
are used as inputs in the GWAMA-based scores, since in this
case we use imputed dosages for GWAMA ‘hits’ that are not dir-
ectly genotyped, and we have imputed dosages with relatively
good imputation quality for all but 3 of the GWAMA ‘hits’ (Supple-
mentary Material, Table S2).
The within-cohort prediction accuracy of dense whole-
genome predictors is higher when we have closer familial rela-
tionships between training and testing samples, with accuracy
in Orkney being higher than accuracy in Croatia for all three traits
(Fig. 2A and B). This is in accordance with Legarra et al. (37), who
ﬁrst demonstrated the predictive value of familial structure in
genomic prediction by considering full-sib families of mice and
showing that accuracy of whole-genome predictors was higher
when each family was split in half between training and testing
data compared with accuracy when each family was put as a
whole either in training or in testing data.
Figure 4. Accuracy of the optimal penalized regression model, the GWAMA-based polygenic score and the meta-model combining the two. y-axis: accuracy is measured
using the Pearson’s correlation coefﬁcient between the predicted and true phenotype of the testing samples (nested cross-validation design for best penalized regression
model, doubly nested cross-validation design for the meta-model). The error bar corresponds to the 95% Conﬁdence Interval (upper CI). abc: denotes statistical
signiﬁcance from a one-tailed paired z-test comparing model performance. Superscript a denotes that a model is not statistically different to the ﬁrst bar of the group,
while superscript b denotes that a model is not statistically different to the second bar of the group. The type of shrinkage and number of input SNPs for the optimal
penalized regression model in each case are given in Table 3.
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The good performance of dense models in within-cohort pre-
diction is most likely due to their ability to capture familial struc-
ture in the data that is predictive of the trait. The effect of
relatedness on prediction accuracy is illustrated in Figure 3
where the predictive correlation of denser models (>100 input
SNPs) is higher when estimated using testing individuals that
have at least one relative in the training data (whole-genome IBS
≥ 0.1) than when estimated using individuals that are nominally
unrelated to the training samples (whole-genome IBS < 0.1). This
difference in accuracy estimated from the ‘related’ and the ‘unre-
lated’ groups is higher in Orkney than it is in Croatia and it is
higher in denser models (RR, many input SNPs) than it is in spar-
ser ones (LASSO, few input SNPs). When we examine the cross-
validation folds, Orkney has both a higher proportion of testing
samples with at least one relative in the training data and a high-
er proportion of testing samples that are related tomultiple train-
ing samples compared with Croatia (Supplementary Material,
Fig. S3). The higher prediction accuracy thatwe observe inOrkney
could therefore be due to the increased relatedness between
training and testing individuals, which would be consistent
with the analytical expressions derived in (25) to quantify the im-
pact of relatedness between training and testing individuals on
the prediction accuracy of G-BLUP (equivalent to RR). The familial
structure tends to be more informative in traits with many small
effects and high heritability, as in these cases the similarity at the
genotyped SNPs tends to be more informative of the (potentially
unobserved) causal loci in related individuals comparedwith un-
related individuals.
Nevertheless, our results using SNP-based pedigree predic-
tors (Supplementary Material, Table S1) suggest that the data
from non-relatives can carry additional predictive information,
which is utilized by the densewhole-genome regressionmodels.
Speciﬁcally, the optimal penalized regression model performs
better than the SNP-based pedigree predictors for all three traits
and both populations, and restricting the SNP-based pedigree to
increasingly more closely related individuals leads to reduced
prediction accuracy in most cases. In this work, we have not ex-
amined prediction based on recorded pedigree, but we note that
SNP-based whole-genome predictors have previously been
shown to outperform genealogy models in humans (24,38). This
has mainly been attributed to two factors. First, recorded pedi-
grees for human cohorts are typically sparse, and therefore lever-
aging predictive signal from the unrelated individuals is helpful.
This is also supported by our comparison of dense whole-
genome models to SNP-based pedigree predictors. Secondly,
similarity based on SNP markers across the genome expresses
the realized genetic relationship between individuals, while simi-
larity based on a recorded pedigree expresses the theoretical ex-
pectation for the genetic relationship between individuals. The
former can be more informative of the realized relationship at
the causal loci in related individuals and thus more predictive
of the trait.
Finally, we note that relatedness between individuals in the
training data can also have an impact on prediction accuracy.
For instance, if we have genetic effects that only occur within a
family (e.g. due to family speciﬁc rare variants), then including
multiple family members in the training data can lead to a
model that represents such effects. These effectswill then gener-
alize to othermembers of the family, butwill not generalize to in-
dividuals outside the family. Hence, the difference in accuracy
estimated from the ‘related’ and the ‘unrelated’ groups in Figure 3
could also be due to a shift in the distribution of effect sizes be-
tween the training data and the testing data in the ‘unrelated’
group.
Pre-ﬁltering
Overall, if we rely on the signal from familial structure to drive pre-
diction, then a dense, whole-genome linear predictor, such as RR or
G-BLUP with all the available SNPs as input, is a goodmodel choice,
especially for traits that have many small genetic effects and high
heritability, such as height. This observation is demonstrated in
Figure 2A and B. For all traits and both populations, RR with all
267 912 input SNPs is either the best or statistically not different to
the optimal penalized regression model, and in height and BMI it
performsbetter thansparsercounterparts.However,wecanalsono-
tice that RR models with 50 000 SNPs—or fewer depending on the
population and the trait—are statistically not different to RRmodels
with all available SNPs inwithin-cohort prediction. Therefore, if it is
beneﬁcial for theﬁnal application, e.g. ifwewant toapplyalgorithms
that scalewith respect to the dimensions, or if wewant to genotype
target individuals at lower coverage, we could perform feature selec-
tion as a ﬁrst step and discard SNPs that are uninformative of the
phenotype, for instance SNPs with an association P-value> 0.8.
Meta-model
A key contribution of our work is the development and evalu-
ation of amethodologically simple meta-model, which improves
prediction by combining two types of genomic signal, the
GWAMA-based risk score and a dense whole-genome predictor
estimated from our population data. When considering the gen-
etic architecture of complex traits, we can contemplate a range of
possible genetic effects in terms of effect size, allele frequency
and mode of action. For instance, we can have alleles that are
common across multiple, potentially admixed, populations and
have large or moderately sized additive effects on a trait. These
are the easiest to identify, estimate and replicate by GWAS. We
can have alleles with very small effects on a trait, or alleles that
are less common, though still present in multiple populations.
Such genetic effects are more difﬁcult to detect by GWAS, but
can be identiﬁed by GWAMAs with an increasing number of
samples. However, we can also have alleles that only appear in
a single population or even a single family, e.g. due to recent mu-
tations, or alleles that only affect a subset of the individuals that
carry them, e.g. due to interaction with a speciﬁc environment or
interaction with a certain genetic background. Our meta-model
demonstrates that prediction accuracy can be improved by com-
bining predictors that capture different parts of the genomic sig-
nal, i.e. different types of genetic effects.
By construction, the GWAMA risk score captures genetic ef-
fects that are large enough tomeet the statistical signiﬁcance cri-
teria in a genome-wide scan and hence, in principle, generalize
across European ancestry populations, even if their absolute ef-
fect sizes differ among populations. On the other hand, the
dense penalized regression models, whereby dense refers to
models with more than 1000 retained SNPs, capture population
(relatedness) structure that is predictive of the trait. The predict-
ive signal in this case is similar to that of a pedigree-based pre-
dictor, which encodes the expected similarity of each pair of
individuals at every locus. In related individuals, due to sharing
of long genetic segments, similarity at the observed genetic loci
is more informative about similarity at the (unobserved) causal
loci compared with non-relatives, and hence more informative
of the phenotypic similarity [this is explored in more detail by
(25)]. We also note that, similar to pedigree-based predictors,
dense whole-genome predictors could be capturing predictive
signal that is due to factors besides linear additive genetic effects,
such as dominance effects and epistasis (39).
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By combining the GWAMA-based polygenic score with a
dense whole-genome predictor, the meta-model represents
both the summary statistics from large GWAMAs and the popula-
tion-speciﬁc statistics fromour data cohorts and always performs
better than either model on its own (Fig. 4). Alternative ways of
combining these two sources of information exist. For instance,
we could ﬁt a whole-genome regression model that treats the
GWAMASNPs as ﬁxed effects, and the remaining SNPs as random
effects. Although other approaches to building on prior knowl-
edge are deﬁnitely worth exploring, we note that many of the al-
ternatives will depend on the choice of predictive models and
resulting optimization algorithms. In contrast, our meta-model
is generic and easily extendible to a broad range of predictive
models trained in possibly different cohorts. A practical implica-
tion of this is that we can improve the accuracy of genetic predic-
tors without the need to access large-scale individual-level data
sets, and we can potentially combine multiple predictors based
on different summary statistics, e.g. combine risk scores based
on multiple GWAS studies if a GWAMA is not available.
Across-cohort generalization
In contrast to within-cohort prediction, in across-cohort predic-
tion sparse models have better generalization performance. Re-
sults from large GWAMAs are therefore key if we want to
construct predictors that are widely applicable, especially for
traits that have many, small genetic effects such as height and
BMI. Nevertheless, our results for across-cohort prediction of
HDL (Fig. 2C and Supplementary Material, Figure S2B) suggest
that—subject to the trait genetic architecture—good generaliza-
tion performance in across-cohort prediction is possible even
with a small training set. In contrast to height and BMI, where
all genetic associations with common SNPs have small effect
size, in HDL we ﬁnd a few common SNPs that have moderate ef-
fect sizes, in addition to a potentially large numberof genetic var-
iants with small effect sizes (Supplementary Material, Fig. S1).
Themoderately sized effects are easier to capture in the Croatian
data and separate from other structure that does not generalize
to Orkney (such as familial predictive signal), compared with
small effects that could generalize to Orkney, but are ‘swamped’
by other structure in the data. Generally, the ability of a model to
generalize to new populations and nominally unrelated indivi-
duals will depend on the trait architecture; for a ﬁnite, relatively
small, number of training samples, the larger and fewer the gen-
etic effects associated with a trait the easier it will be for a model
to separate this predictive signal from other data structure. Add-
itionally, generalization performancewill depend on the suitabil-
ity of themodel with respect to the target population. Aswe try to
predict increasinglymore distantly related individuals—from ‘re-
lated to the training data’ to ‘nominally unrelated but from the
same geographic location’ to ‘nominally unrelated and from a
different geographic location’—we expect that fewer effects will
generalize, and thus sparser models are likely to perform better.
Denser models will tend to ﬁt the training data more closely, but
some of this captured signal is likely to be irrelevant in a distantly
related population, thus introducing noise in the prediction,
which can be interpreted as a form of over-ﬁtting. For instance,
in the case of HDL, the very sparse models (<5 SNPs in the solu-
tion) capture only the moderately sized genetic effects. The
densermodels include these genetic effects, but also capture pre-
dictive familial structure from the Croatian data set, which does
not generalize to Orkney.
Our results in across-cohort prediction of HDL are consistent
with (22) who found that sparse models (including from 20 to 100
SNPs) were optimal for genomic prediction of HDL in two cohorts
comprising unrelated individuals. In our experiments, the opti-
mal models for across-cohort prediction of HDL are sparser
(including from 3 to 5 SNPs). This can be due to the difference
in the available genotyped SNPs in the two studies, the increased
power of the study in (22) to distinguish SNPs tagging causal loci
with smaller effects [the cohorts in (22) are larger and comprise
unrelated individuals, which reduces other types of predictive
signal in the training data], or a difference in minor allele fre-
quencies (MAFs) in the different cohorts. Indeed the MAFs of
the three SNPs retained in the optimal LASSO model are higher
in Orkney than in Croatia (Table 2) and thus we can expect that
a larger proportion of phenotypic variation will be attributable
to these three SNPs in Orkney. This can also explain why the 3-
SNP LASSOmodel achieves higher prediction accuracy in Orkney
than in Croatia (Figure 2A and C), even though it is trained using
samples from Croatia. Overall, we expect that the optimal num-
ber of input SNPs may increase with larger sample sizes, as we
havemore power to detect and estimate genetic effects. However,
we also expect that there is a global optimum for the number of
input SNPs, which is trait-depend.
Finally, our results in across-cohort prediction of HDL illus-
trate the importance of the validation data set. In the sparse
models (LASSO and EN) if we select the penalty strength using
aheld-out set of individuals from the target population at the val-
idation step, thenwe can get good generalization performance on
the testing individuals irrespective of the numberof SNPs that are
given as input to themodel (SupplementaryMaterial, Figure S2B).
This is an important point for a real-world application, as we
could for instance have a number of different predictors and se-
lect the optimal one by comparing performance on a small num-
ber of individuals from the target population.
Opportunities and future work
Thepenalized regressionmodels thatwe consider in our studyare
based on the conventional oversimplifying assumption that the
phenotypic observations are independently and identically dis-
tributed (i.i.d.) given the genotypes and the model parameters.
Table 2.MAFs of the three SNPs retained in the LASSOmodel with the
highest accuracy in across-cohort prediction of HDL
Rsid MAF in Orkney MAF in Croatia
rs3764261 0.3909 0.3138
rs1532624 0.4922 0.4099
rs7499892 0.2292 0.1631
The three SNPs have a higher minor allele frequency (MAF) in Orkney compared
with Croatia and thus we expect thatmore phenotypic variance will be explained
by these three SNPs in Orkney.
Table 3. Type of shrinkage and number of input SNPs for the optimal
penalized regression model in within-cohort prediction
Height
Croatia
BMI
Croatia
HDL
Croatia
Height
Orkney
BMI
Orkney
HDL
Orkney
Type of
shrinkage
Ridge Ridge Ridge Ridge Ridge Elastic
Net
Number of
input SNPs
100 000 1000 25 000 25 000 200 000 100 000
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In other words, we assume that the mapping (learned model
parameters) from SNPs to the phenotype is homogeneous and
identical for all individuals in the sampled population, and that
for any individual a genetic prediction of their phenotype de-
pends only on the learned mapping and that individual’s geno-
type. When we have related and unrelated individuals in the
training data, this assumption may not hold, as samples from
the same family may exhibit internal dependencies. The i.i.d. as-
sumption can also be limiting in other practical situations; e.g. if
different genotypic markers or different mappings are predictive
in different strata of the population. In the future,wewill consider
approaches that either explicitly model known internal depend-
encies—e.g. mixed-effects models with families ﬁtted as random
effects—or allow for non-homogeneous mappings to be learned
from the data—e.g. by combining regression with a clustering
method. Additional information may be needed in order to
learn these more complex models, as the small sample size of
our data sets poses a statistical limitation. For instance, informa-
tion frommultiple correlated traits could help infer potential sub-
groupingswhen the source of internal dependencies is unknown.
Another interesting direction we plan to investigate in the fu-
ture is the construction and evaluation of models that incorpor-
ate summary statistics from large GWAMAs in different ways. In
this study, we showed that by combining dense whole-genome
predictors with GWAMA-based polygenic scores in a simple
meta-model, we achieve higher prediction accuracy than by
using either model on its own. In light of this ﬁnding and given
the increasing number of GWAMA studies becoming available
through the organization of large consortia for different complex
traits, we believe that comparing different ways of incorporating
information from summary statistics into predictive models is
an interesting research direction. For instance, we could use
GWAMA summary statistics to deﬁne informative prior distribu-
tions for SNP effects, or to (re)-weight the SNP contributions, e.g.
similar to theweighted G-BLUPmodel proposed in (25). Establish-
ing the optimal way of combining external summary statistics
with data statistics is of practical importance as it can lead to im-
proved genomic predictorswithout the need to access large-scale
individual-level data.
Furthermore, we believe that our meta-model is a simple, yet
effective approach for combining predictors based on different
data sources. Here, we only considered the combination of a
dense, whole-genome predictor with the GWAMA-based risk
score. Depending on which sources of data are available, other
predictors and combinations could also lead to improved predic-
tion accuracy, including predictors based on a recorded pedigree,
and combinations of dense with sparse models estimated from
the same or different data. For example, if we have data from dif-
ferent cohorts, we could consider combining a number of sparse
predictors, each estimated using the data from a single cohort,
and then learn the combination weights using a few individuals
from the target cohort.
The GWAMA-based polygenic risk scores that we evaluated in
this work are constructed using only the SNPs whose P-value of
association passes the Bonferroni-corrected signiﬁcance thresh-
old in the GWAMA for each trait. However, as already discussed
this is a stringent threshold and potentially leads to false nega-
tives.We could therefore consider risk scores based on less-strin-
gent thresholds. This is examined in (40) who ﬁnd that using a
less stringent threshold for the inclusion of SNPs to a polygenic
risk score of schizophrenia results in a higher proportion of the
variance in case–control status of testing individuals being ex-
plained. However, if we use GWAMA summary statistics and
evaluate our risk scores in cohorts that have been used in the
GWAMA study, thenwe need to be careful with the interpretation
of our estimate of the prediction accuracy, especially if we are
using denser risk scores resulting from applying a less-stringent
threshold for selecting SNPs. The overestimation of prediction
accuracy occurring when the testing individuals have been
used in the marker selection step is examined in (26) and (41),
who show that one of the important factors deﬁning the amount
of upward bias in the prediction accuracy is the number of SNPs
included in the model.
Another important considerationwhen constructing GWAMA-
based risk scores ishow todealwith the LDstructure. Selecting the
SNPs based on univariate statistics can lead to redundancy in the
selected SNPs, while using arbitrary cut-off thresholds can result
in either uninformative data being used or useful information
being ignored. An alternative to using the published summarysta-
tistics to directly construct a GWAMAscore is to use themas priors
for the amount of shrinkage applied to each SNP in penalized re-
gression models. Incorporating GWAMA summary statistics as
priors in penalized regression models could remove the need to
account for LD structure, since in these models the effects of all
SNPs are estimated jointly, while taking advantage of the predict-
ive information coming from the large sample size of GWAMA
studies by applying differential shrinkage to the input SNPs.
Finally, an important limitation of genomic predictors comes
from the heritability of the trait (26). By deﬁnition, a complex trait
is inﬂuenced by many factors, both genetic and environmental.
Therefore, the proportion of trait variation that is due to genetic
factorswill always limit the accuracywe canachievewith a genetic
predictor. The genomic predictors we developed perform statistic-
ally better than simply predicting the mean phenotype in many
scenarios, certifying that there is an underlying predictive signal
in genomic data. Therefore, identifying how we can use the pre-
dictive signal from genomic data as leverage into existing clinical
models may lead to faster implementation of genomic ﬁndings
in medical decision-making for complex traits. In the future, we
will investigate how we can improve prediction accuracy in com-
plex traits by combining genomic data with intermediate pheno-
types, such as gene expression and methylation, similar to the
OmicKriging method developed by Wheeler et al. (42). Such inter-
mediate phenotypes can mediate the predictive signal from the
genomic data, but also capture a proportionof the phenotypic vari-
ation that is due to current or past environmental inﬂuences.
Conclusion
In this work, we focused on genetic predictors of complex traits
and assessed performance under different scenarios with re-
spect to trait architecture and population structure, mainly in
terms of relatedness. Themainmotivation for considering genet-
ic predictors is their potential beneﬁt to clinical decision-making
as implemented in a ‘personalized genomic medicine’ scenario.
Although the genomic predictorswe developed perform statistic-
ally better than chance in many scenarios—certifying that there
is an underlying predictive signal in genomic data—the predict-
ive accuracy of ourmodels is still low for clinical decision-making
at the level of the individual. However, the creation of national
biobanks potentially linked withmedical data from general prac-
tice,will openupnewopportunities for genomic prediction, as hav-
ing related individuals with recorded genotypic and phenotypic
information will be likely for a large proportion of the population.
The results from the meta-model we developed demonstrate that
by combining dense whole-genome predictors with GWAMA-
based risk scores we can improve prediction accuracy. Hence gen-
omic predictors can be improved using summary statistics and
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without requiring access to large individual-level data sets, which
are often difﬁcult to share due to practical, legal and ethical consid-
erations. The meta-model is a way of performing predictive meta-
analysis for optimizing genomic predictions, and we believe that
it can be extended to combinemultiple information sources, poten-
tially involving non-SNP data.
Materials and Methods
Data set description and pre-processing
In this work, we consider two data sets comprising measured
phenotypes and genotypes of individuals from two European
countries, Croatia (South-East Europe) and Scotland (North-
West Europe). The ﬁrst data set comprises individuals recruited
in three locations in Croatia, the Dalmatian islands of Vis (43)
and Korcula (44) and the mainland city of Split (45). We refer to
this data set as ‘Croatia’. The second data set comprises indivi-
duals recruited in the isolated Scottish islands of Orkney as
part of the Orkney Complex Disease Study (ORCADES) (46) and
we refer to it as ‘Orkney’. In all cohort studies individuals were
recruited irrespective of any speciﬁc phenotype. However, in Ork-
ney and to a lesser extent in Vis and Korcula emphasis was given
in recruiting family members of existing participants.
Phenotypes
The traits we examine are height, body mass index (BMI) and
high-density lipoprotein (HDL) cholesterol level. After removing
individuals with extreme phenotypic measurements (values
more than three standard deviations away from the population
mean), the number of samples that have measurements for all
three traits are 2186 in Croatia (Korcula = 816, Vis = 897, Split =
473) and 831 in Orkney. We log-transform the raw HDL measure-
ments, in order to have phenotypic values that are normally dis-
tributed. Furthermore, we adjust each trait for the effects of sex,
age and age squared within each cohort using a linear, additive
model. Finally, we standardize the residuals from this analysis
within each cohort. Overall, the phenotypes we consider in our
prediction models are standardized residuals of the (log-trans-
formed for HDL) measurements for each trait. We use only the
training data to estimate the parameters of the linear model
and the populationmean and standard deviation that are subse-
quently used to adjust and standardize all data samples, unless
explicitly stated in the text.
In principle, we can include covariates such as sex and age as
inputs into the prediction models, and estimate the effects of
these covariates andof the SNPs simultaneously. There are several
practical advantages inpre-adjusting for these covariates. First,we
candirectly assess the predictionaccuracydue to the genetic com-
ponent, a correlation higher than zero (or a mean squared error
smaller than one in the case of a standardized phenotype) sug-
gests that the SNPs are informative of the trait. If we include the
covariates as inputs then we need to compare performance over
a baselinemodel that only considers the covariates, in order to as-
sess any improvement in prediction accuracy attributable to the
SNPs. Second, pre-adjusting for the covariates allows us to take
into account more complex dependencies among these covari-
ates, especially when we have multiple cohorts. We know from
epidemiological studies that the effects of such covariates can be
different in different populations. If we want to ﬁt a model using
samples from multiple populations, we therefore need to ﬁt not
only the covariates, but also possible interaction effects between
the covariates and a population index. This is particularly relevant
when we analyse the Croatian cohort, which comprises samples
from three sub-populations in Croatia. Finally, using pre-adjusted
phenotypes can facilitate comparison with models that do not
model inputs in the same way as a linear parametric model, e.g.
kernel methods employing non-linear kernel constructions. Po-
tential disadvantages of pre-adjusting the phenotypes for covari-
ates include the difﬁculty in interpreting how the predicted values
relate to the true phenotypic scale, and the possible misspeciﬁca-
tion of our models if there are interactions between the pre-ad-
justed covariates and the genetic effects.
Genotypes
All populationswere genotypedusing IlluminacommonSNParrays.
Vis was genotyped using the Illumina Inﬁnium HumanHap300
BeadChip. The majority of Orkney samples were also genotyped
using this chip with the remainder genotyped using the Illumina
HumanHap370CNV duo chip. Korcula and Split were genotyped
on the IlluminaHumanHap370CNVduoandquad chips, respective-
ly. We performed quality control in each cohort, excluding indivi-
duals with a call rate below 97% and SNPs with a call rate below
98%, or with a MAF of <1%, or when the P-value for deviation from
Hardy–Weinberg equilibrium is smaller than 1 × 10−6. Following
thesequality control steps,wehave 267 912 SNPs that are genotyped
inall theCroatian sub-populations and260 562 of themarealso gen-
otyped in Orkney. When we estimate the genomic predictors using
our data sets, we standardize the genotypes using the frequency of
theminor allele. Let pj be theMAF of SNP j, and xij ∈ f0; 1; 2g denote
the counts of theminorallele at SNP j for some individual i. Then the
MAF-adjusted genotype is given by bxij ¼ ðxij  2 pjÞ=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2 pjð1 pjÞ
q
:
We note that with penalized regression methods such as LASSO
and RR, the coding of the genotypes has an impact on model per-
formance, as the penalty applied to each coefﬁcient depends on
the scale of the covariate. By standardizing the genotypes,we effect-
ively impose the same penalty on all the SNPs. In experiments that
use samples from both Croatia and Orkney, we do not use the 7350
SNPs that are not genotyped in Orkney. For the GWAMA-score con-
struction, SNPs that are not genotyped (i.e. not included in the
267 912 SNPs) are imputed based on the 1000 Genomes data set. Im-
putation of ∼39 million SNPs and insertions/deletions was com-
peted for Vis, Korcula, Split and ORCADES using the ‘ALL (Phase 1
integrated release v3, April 2012)’ reference panel. SHAPEIT (47) ver-
sion 2was used for pre-phasing because it can partially utilize pedi-
grees to improve thephasing for related individuals. Imputationwas
completed using IMPUTE2 (48).
Ethics statement
All the Croatian cohorts, referred to as Vis, Korcula and Split, re-
ceived ethical approval from the Ethics Committee of theMedical
School, University of Split and the NHS Lothian (South East Scot-
land Research Ethics Committee). The ORCADES study, referred
to as Orkney, received ethical approval from the NHS Orkney Re-
search Ethics Committee and North of Scotland Research Ethics
Committee. All studies followed the tenets of the 1975 Declar-
ation of Helsinki and all participants gave written informed con-
sent prior to participation.
General prediction setting
The common case in genomic predictions of complex traits is to
have a data set D comprising n individuals, whose genotypes at a
number of loci are measured along with the phenotypic value of
interest. Measurements for additional covariates, such as age and
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sex, are often available.Wewill refer to suchdatameasurements as
‘side information’. These are not directlyof interest, but can beused
as covariates in themodel—in which case the resulting predictor is
not solely based on genomic information—or they can be used to
‘adjust’ the phenotype prior to building a predictive model—in
which case we want our model to capture the genomic signal that
is predictive of the phenotype of interest and disregard any genom-
ic signal that is predictive of the side information.
Wewill denote this data set by D ¼ fyi; xi; ziji ¼ 1:::ng; where yi
is the phenotype of individual i, xi is a vector of genotypes for
individual i, with xij ∈ f0; 1; 2g denoting the counts of a speciﬁc
allele at SNP j, and we assume that all markers are diallelic, and
zi is a vector with measurements of side information for individ-
ual i. Note that we consider a univariate phenotype of interest,
i.e. yi is scalar. Given such a data set D, our aim is to construct a
predictivemodel, which given the genotypes of a new individual,
x*, and any side information, z* (if our predictor is not solely gen-
omic), can give us a prediction about the unobserved phenotype,
y*. In this work, we consider quantitative traits with continuous
phenotypes, hence the prediction task can be speciﬁed as a re-
gression problem. To this end, the statistical models used in
quantitative genetics to describe the variation of a phenotypic
trait are of the following form (16):
yi ¼ f ðxi; zijθÞ þ εi; εi ∼ N ð0; σ2εÞ; ð1Þ
where f ðxi; zijθÞ is a function modelling the effects of the genetic
and side information on the phenotype, θ is a vector of parameters
that we typically want to estimate from our data, and ε is a model
residual, assumed to be independently and identically distributed
(i.i.d.) from a normal distribution, withmean 0 and variance σ2ε : In
quantitative genetics, ε is assumed to includeall sources ofpheno-
typic variation that are omitted from f ðxi; zijθÞ and it is often re-
ferred to as the ‘environmental component’ of a phenotypic
trait, i.e. some randomsourcewhich is independent fromthe ‘gen-
etic component’ and side informationmodelled through f ðxi; zijθÞ.
In thiswork, we pre-adjust the phenotypeswith respect to side
information, so that yi is a standardized residual, resulting from
adjusting the original phenotype for the effect of sex, age and
age squaredandsubsequently centring and scaling to (0, 1). There-
fore, our statistical model of the phenotype can be simpliﬁed as:
yi ¼ gðxijβÞ þ εi; εi ∼ N ð0; σ2εÞ; ð2Þ
where gðxijβÞ is a functionmodelling genetic effects on the pheno-
type.We note that the residual variance, σ2ε ; is different to that ap-
pearing in Equation (1), but we have used the same notation for
simplicity. Furthermore, we only consider a linear, additive
model for this ‘genetic component’ of phenotypic variation, with
gðxijβÞ ¼
XP
j¼1
βjxij; ð3Þ
where P is the number of SNPs that we consider, and βj is the
partial regression of the phenotype on SNP j.
There are several ways of selecting the genomic markers that
enter Equation (3) and of estimating the parameter vector β.
Here, we consider two methodologically distinct approaches; a
GWAMA-based polygenic score, which is entirely based on results
from the literature, and a range of penalized regression models
with and without pre-ﬁltering of markers, which are entirely
based on estimation procedures using our own data.
GWAMA-based polygenic score
This score is constructed using results from large GWAMA that
evaluate the univariate association of each marker (SNP) with
the phenotype based on more than 100 000 individuals and
often exceeding 200 000. For each trait, we only use the SNPs
that are reported as signiﬁcant associations in the corresponding
GWAMA article. We construct the polygenic score for each indi-
vidual by adding the number of reference alleles he or she carries
at the selected SNPs, pre-multiplied by the corresponding SNP
effect sizes reported in the GWAMA article.
More speciﬁcally, to construct the GWAMA-based polygenic
score for height, we use the 180 SNPs identiﬁed by the GIANT
Consortium and reported in Supplementary Material, Table S1
of (33), together with the reported effect sizes (Beta from
Stage 1 + Stage 2, in the aforementioned table). Similarly, for
the BMI GWAMA-based polygenic score we use the 32 SNPs re-
ported in Table 1 of (34), with effect sizes taken from the ‘per al-
lele change in BMI’ column. Finally, for the HLD GWAMA-based
polygenic score, we use 70 SNPs reported as associated with
HDL in Tables 1–4 and Supplementary Material, Table S3 of
(35), together with the reported effect sizes that correspond
to HDL.
When the reported SNPs are not included in our genotyping
array, we use allelic dosages—imputed using the 1000 Genomes
reference data and the existing genotype data—to construct the
GWAMA scores. In fact, <30% of the reported SNP ‘hits’ for each
trait are genotyped in our data (22 out of 180 in height, 7 out of
32 in BMI and 20 out of 70 in HDL). However, imputed dosages
with relatively good imputation quality are available for the
non-genotyped SNP ‘hits’ and used for the GWAMA score con-
struction, with the exception of three height SNP ‘hits’ whose
position does not exist in the genome build of the 1000 Genomes
data set used to perform the imputation.
A list of the GWAMA ‘hits’ for each trait, together with infor-
mation on genotyping status, imputation quality and the
GWAMA estimated beta coefﬁcients that we used to construct
the scores is given in Supplementary Material, Table S2.
We note that the Croatia and the Orkney cohorts are used in
the GWAMA studies of all three traits, and hence the prediction
accuracy of the GWAMA score will have an upward bias (26).
Given that the number of individuals used to estimate the
GWAMA effects is large (>100 000) and that we only use a small
number of SNPs (180, 32, 70 for height, BMI andHDL, respectively)
this bias will be small.
Penalized regression methods
We examine two of the most commonly used shrinkage estima-
tion methods, namely RR (30)—equivalent to the (Genome-
enabled) Best Linear Unbiased Predictor, (G)-BLUP (19), which is
widely used in animal and plant breeding—and the Least Abso-
lute Shrinkage and Selection Operator (LASSO) (31). We also
examine a combination of these two estimationmethods termed
the ElasticNet (EN) (32). The Least-Squares solution for themodel
deﬁned by Equations (2) and (3) is given by
argβmin
Xn
i¼1
yi 
XP
j¼1
βjxij
0
@
1
A
2
; ð4Þ
i.e. to get the best ﬁt for data setD, we adjust the values of the par-
ameter vector β so as to minimize the sum of the squared terms
of model residuals.
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The solution in Equation (4) minimizes the prediction error
in data set D. However, what we are interested in is whether a
model has good predictive performance in new, unseen data
points, i.e. we are interested in whether a model generalizes
well. In penalized regression models, generalization is achieved
by introducing a regularization (penalty) term to the least
squares objective, which pushes the resulting model towards a
smoother underlying function, by shrinking the model para-
meters towards 0. The implicit assumption is that the underlying
process that generates the data is ‘smoother’ than what the data
actually suggests, and thus the penalty term prevents the model
from ﬁtting the noise in the data, a problem also referred to as
over-ﬁtting. The objective function now has two components
argβmin
Xn
i¼1
yi 
XP
j¼1
βjxij
0
@
1
A
2
þ λrðβÞ; ð5Þ
where rðβÞ is the penalty term and λ is ameta-parameter control-
ling the amount of regularization. The penalty term introduces
some bias to the least-squares solution, preventing the βj’s
from ﬁtting the data points in D perfectly. However, too much
regularization will also lead to ignoring the signal in the data,
and thus the optimal λ should be chosen according to a validation
set, as discussed in the section Experimental procedure and evalu-
ation. Assigning a prior distribution over the model parameters
and inferring quantities of interest by computing their posterior
distribution, can also achieve regularization.
The three methods we examine have different penalty terms.
RR has an ‘2 penalty term, rðβÞ ¼
PP
j¼1 β
2
j ; which results in a dense
model, meaning that all the P markers are assigned a non-zero
weight, albeit shrunk. LASSO has an ‘1 penalty term, rðβÞ ¼PP
j¼1 jβjj; which results in a sparse model, meaning that a lot of
markers are given a 0 weight, and thus no longer contribute to the
predictive model. A sparse solution can be advantageous, as it is
more interpretable and easier to implement—we need to genotype
fewermarkers tomakepredictions innew individuals.However, the
LASSO penalty tends to select only one variable froma group of cor-
related variables and could therefore prunemarkers that carry add-
itional information if they are in high LD with markers already
included in the solution. The EN combines the RR and LASSO
penalties, and overcomes this limitation, while still leading to a
sparse solution when compared with RR. The EN penalty term
is rðβÞ ¼ αPPj¼1 β2j þ ð1 αÞPPj¼1 jβjj, where α is a second meta-
parameter controlling the proportion of ‘1 to ‘2 penalty. We refer
the reader to (19) for a broader overview of shrinkage estimation
methods, both point estimates and Bayesian methods, that have
been used in the context of genomic predictions to infer the para-
meters of the model deﬁned by Equations (2) and (3). Interestingly,
the LASSO and the RR solutions can be derived as themaximum-a-
posteriori estimates when placing a Laplace and a Gaussian distri-
bution as prior over the model parameters, respectively.
Finally, we note that the problem of over-ﬁtting, and hence
the need for regularization, is particularly prominent when we
want to ﬁt a complex model with relatively few data points
(here, individuals). In the context of genomic predictions, this
problem is relevant when we consider whole-genome regression
methods. This is often referred to as the ‘large p small n’ situ-
ation, where the number of model parameters, βj’s, corresponds
to the number of genomic markers, P, and is typically one or two
orders of magnitude larger than the number of samples (indivi-
duals), n, in a data set. When P >> n, the solution to the least
squares objective in Equation (4) will ﬁt the data points in D
perfectly. However, a lot of the βj’s will be describing the ‘noise’
in D, i.e. unique idiosyncrasies of the speciﬁc data set, which do
not generalize in the overall population.
GWAS-based pre-ﬁltering of SNPs
A different approach for addressing the problem of over-ﬁtting is
to pre-ﬁlter the genomicmarkers, that is, to select in advance the
markers to be used as explanatory variables in the regression.
This can be done by ranking the markers according to some use-
fulness criterion and using only the topmmarkers in the predic-
tion model deﬁned by Equation (2). This pre-selection step is
often termed as ‘feature selection’ and is an important step in
most applications of statistical learning.
Here, we pre-select markers by computing the association
between each SNP and a trait and selecting the m SNPs with the
lowest P-values of association, where m ∈ f5; 10; 100; 500; 1k;
10k; 25k; 100k; 200kg and k denotes thousands. The P-value of as-
sociation is computed using the full training data set in each
scenario, with the following exception where only a subset of
the training data set is used. In the experiment where we add
the Croatian samples to the training folds of the within-cohort
nested cross-validation procedure in Orkney, we use the P-values
estimated using the Orkney training data only. In this case, the
Croatian samples are only used during the training of the pena-
lized regression models and not during the GWAS pre-ﬁltering.
This GWAS-based pre-ﬁltering does not take LD into account,
i.e. it selects themmost associated SNPs, rather than themmost
associated independent loci. However, this pre-ﬁltering procedure
is simple to implement—it does not require characterization of
the LD structure, which can be computationally expensive, or
evaluation of different LD thresholds—while the potential redun-
dancies in the selected SNPs can be dealt with by the penalized
regression methods, which estimate the SNP effects jointly, and
tend to shrink the parameters of correlated variables that do not
contribute complementary predictive signal.
Meta-models
In statistical learning, we can often achieve better predictive per-
formance by combining the predictions from multiple models.
This is often called model averaging (49) or ensemble learning
(50,51) and the main idea is that each model in the ensemble
makes different assumptions about the underlying mappings
and possibly explains only a part of the data structure. By com-
bining multiple models in a ﬂexible way, we can produce a stron-
ger model that explains more of the data structure.
Here, we construct such an ensemble by combining the
GWAMA-based polygenic score with the best shrinkage model
estimated using our data sets. The main motivation is to test if
these two predictors combined can achieve higher prediction ac-
curacy than either of the predictors on its own. If that were the
case, it would mean that they capture different aspects of the
data structure that is predictive of a phenotype.
More speciﬁcally, let us consider a single trait, and let cyijS de-
note the polygenic score for individual i, and cyijR denote the pre-
dicted value for individual i under the best penalized regression
model, where the optimal model is selected using an independ-
ent, validation data set. Then, a simple meta-model that com-
bines these two predictors is given by
yi ¼ βScyijS þ βRcyijR þ εi; εi ∼ N ð0; σ2εÞ; ð6Þ
where βS and βR are parameters of themeta-model that we need to
Human Molecular Genetics | 13
 at Edinburgh U
niversity on M
ay 22, 2015
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
estimate from data, and Yi is the phenotype of individual i. Again,
the residual variance, σ2ε ; is different to that appearing in Equation
(1) and in Equation (2), butwehaveused the samenotation for sim-
plicity.We estimate βS and βR using ordinary least squares. We dis-
cuss the data partition scheme for training and evaluating the
meta-model in the section Experimental procedure and evaluation.
Model comparison
To compare model performance, we apply the Fisher z-trans-
formation on the correlation coefﬁcient corresponding to each
model. Given zM1 and zM2 for models M1 and M2, we test if
model M1 is better than model M2 by performing a one-tailed
paired z-test. Statistical signiﬁcance is evaluated at the 0.05
P-value threshold.
Experimental procedure and evaluation
In order to get an unbiased estimate of prediction accuracy in
new unseen individuals, we need two mutually exclusive data
sets: a training set which we use to perform feature selection
and to estimate model parameters, and a testing set which we
use to estimate the prediction accuracy of our predictive model.
A third data set is additionally needed when wewant to perform
model selection, i.e. whenwe consider a range of candidate predict-
ive models and want to select the best among them for deploy-
ment. This data set is called the validation set and is used to
compare the performance of candidatemodels ormodel settings.
It is important to note that in the validation step, our choice of the
optimal model could be inﬂuenced by randomness in the data set
[see, e.g. (52) for an application of bagging in GBLUP]. Therefore, if
all candidate models and settings are equally likely a priori, then
the accuracy of the optimal model on the validation set describes
the best-case scenario, rather than themost likely scenario. To get an
unbiased estimate ofmodel performance in newunseen data, we
need to measure performance on a data set that has not been
used for any decision-making.
Furthermore, as pointed out in (26), to get an estimate of the
prediction accuracy that we can expect in a target population,
we need to perform this estimation using samples from that tar-
get population. Herewe consider two scenarios,within-cohort pre-
diction, in which case the training, validation and testing sets
come from the same population cohort, and across-cohort pre-
diction, in which case the training and testing sets come from dif-
ferent populations and the validation set comprises samples
either from the training or from the testing population. In each
scenario, we assume that the target population is the same as
the testing population and examine how well different models
generalize for different target populations andwhat are the char-
acteristics of the trait that make such generalization possible.
Inwithin-cohort prediction, we use nested cross-validation to
split the data into training, validation and testing sets. In the
‘outer’ cross-validation phase, we split the data in 10 mutually
exclusive folds, so that each 10% of the data samples is a separate
testing set. In the ‘inner’ cross-validation phase, the remaining
90%of the data in each fold is further split into 5-folds for the pur-
pose of training and validation; each training set comprises 72%
of the data samples and each validation set comprises 18% of the
data samples. Once model selection is performed, we join the
validation and training samples and re-estimate the parameters
of the optimalmodel using the full 90% of the data samples. Simi-
lar to (22), we perform model selection by running the inner
cross-validation on a single randomly selected outer fold. This
reduces the computational burden from 5 × 10 = 50 model
computations to 5 + 10 = 15 model computations, and is found
to be sufﬁcient formodel selection in similarwork (22). A pictorial
representation of the nested cross-validation procedure is given
in Supplementary Material, Figure S4.
In across-cohort prediction, the training and testing samples
are independent by construction, as they come fromdifferent po-
pulations. For the validation set, we consider two scenarios. First,
the validation set comprises individuals from the training popu-
lation. In this case, we use the results from the ‘outer’ 10-fold
cross-validation to select the optimal model and then use the
full training population data set to estimate the parameters
of this optimal model and compute the prediction accuracy on
the testing data (Supplementary Material, Fig. S5). In the second
scenario, the validation set comprises individuals from the target
(testing) population. In this case, we use a 10-fold split of the tar-
get population samples and use 90% to select the optimal model
(validation set) and the remaining 10% to assess the prediction
accuracy (testing set). Themodels are trained using the full train-
ing population data set (Supplementary Material, Fig. S6).
Finally, to estimate theparameters of themeta-models,we fur-
ther split each testing fold from within-cohort prediction in 10
sub-folds and perform a cross-validation experiment to train the
meta-model and assess its performance. The same testing sam-
ples are used to evaluate the performance of the single models
and of the meta-models, but in the meta-models an additional
data split is applied to perform the meta-training. Speciﬁcally,
each testing fold (10% of the full data set) is split in meta-training
andmeta-testing samples, where themeta-training set comprises
9%of the full data set and themeta-testing set comprises 1%of the
full data set (Supplementary Material, Fig. S7). This gives rise to a
100-fold cross-validationprocedure: 10 testing folds, each split in a
further 10 meta-folds, and is equivalent to a doubly nested cross-
validation procedure, where 1% of the data is left-out for evaluat-
ing the accuracyof themeta-model and the remaining 99% is used
for training, validation and testing purposes. We note that 9% of
the data is a small sample, but themeta-model only has two para-
meters, and hence estimation is possible.
The optimal penalty strength, λ, for the shrinkage models is
selected using grid search. For LASSO and the EN, we consider
λ ∈ f0:0025; 0:005; 0:0075; 0:01; 0:025; 0:05; 0:075; 0:1; 0:25g × n; and
for RR, we consider λ ∈ f0:01; 0:05; 0:1; 0:5; 1; 10;50; 100; 250; 500;
1000; 1500g × n; where n is the number of samples in the training
set. To select the range of λ values for each model, we performed
preliminary experiments using 500 randomly selected samples
from the Croatian cohort. We evaluated performance using λ va-
lues with different orders of magnitude and expanded the range
of valueswhenperformancewas optimal (or close to the optimal)
at either end of the spectrum. Amore automatedway of suggest-
ing a good sequence of λ values is described in (53). Themain idea
is to compute the smallest λ value, λmax, for which all coefﬁcients
are shrunk to zero, select aminimum λ value, λmin, and evaluate a
sequence of K values for λ decreasing from λmax to λmin on the log
scale. The suggested values for λmin and K are λmin = 0.001 × λmax
and K = 100. The meta-parameter α that controls the proportion
of ‘1 to ‘2 penalty in EN is optimized using grid search over
α ∈ f0:2; 0:4; 0:6; 0:8g: In principle, the EN can attain the LASSO
and the RR solutions as special cases. However, herewe constrain
the EN solution to have non-zero contributions from both the ‘1
and the ‘2 penalty terms, sincewe are already evaluating the per-
formance of RR and LASSO separately.
Throughout this article, we measure prediction accuracy
using the Pearson’s correlation coefﬁcient between the true and
the predicted phenotypes of the testing samples. When we use
cross-validation, the predictions of the testing data from all the
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folds are jointly considered to compute the correlation. Note that
although we do not report prediction accuracy on the validation
set, this is used to select the meta-parameters λ and α in the
shrinkage models, as well as the optimal number of input SNPs
and the shrinkage type (denoted by the black ‘x’ symbol in Fig. 2).
Supplementary Material
Supplementary Material is available at HMG online.
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